Navigation Links
Microarray sequence capture speeds large-scale resequencing of targeted genomic regions
Date:10/15/2007

Researchers at Baylor College of Medicine and Roche NimbleGen Inc., a fully integrated part of Roche Applied Science, today have published details of a highly efficient and cost-effective method for capturing targeted regions of the genome via NimbleChip microarrays in preparation for high-throughput 454 Sequencing. The technology, called sequence capture, enables fast and accurate enrichment of thousands of selected genomic regions, either contiguous or dispersed, such as segments of chromosomes or all genes or exons. The study, entitled Direct Selection of Human Genomic Loci by Microarray Hybridization, appears online (ahead of print) in the journal Nature Methods1.

In light of the success of the current sequence capture technology, Baylors Human Genome Sequencing Center (HGSC) has signed on as an early access customer to Roche NimbleGens sequence capture technology. As presented on October 10, 2007, at the J. Craig Venter Institutes Genomes, Medicine, and the Environment (GME) conference, Roche NimbleGen and 454 Life Sciences, working with Dr. Richard Gibbs, professor and Director of the HGSC, will create a whole-genome human exome (all exons) microarray, with the goal of resequencing the entire human exome.

Resequencing of genes or other genomic regions of interest is a key step in detecting mutations associated with various complex human diseases, such as cancer, asthma and heart disease. The predominant method for selection of specific genomic regions for resequencing has primarily relied on PCR (polymerase chain reaction) to enrich for specific DNA fragments. However, PCR is limited in the length of sequence it can amplify, is difficult to scale or multiplex for the enrichment of thousands of fragments, and has limited performance in the repetitive regions typical of complex genomes, such as human. The sequence capture microarray technology bridges the gap between next-generation DNA sequencing technology and current sample preparation methods by providing an adaptable, massively parallel method for selective enrichment of genomic regions of interest. Roche NimbleGens sequence capture technology enables high-performance targeting of thousands of specific genes or loci using a single microarray hybridization-based enrichment process. The Baylor study1 used Roches Genome Sequencer FLX System to quickly and affordably sequence the enriched genomic regions for downstream analysis. 454 Sequencing technology is ideal for this targeted sequencing approach because of its long read lengths and highly accurate reads.

This new technology will replace polymerase chain reaction (PCR) for many purposes, said Gibbs. If the aim is to sequence a whole genome for everybody, this is a huge step in that direction.

The Nature Methods paper published by Baylor1 demonstrates that the sequence capture process is simpler, more accurate, more efficient and more cost-effective than the multiplex PCR that was previously used to prepare genomic samples for sequencing. In one experiment, more than 6,700 exons (the part of the genetic code that together form genes), were enriched and analyzed, as well as contiguous genomic regions of up to 5 million bases. Using the old technology this would have taken at least six months.

"Were delighted to have an opportunity to collaborate with scientists at Baylor HGSC on the development of this breakthrough technology," said Dr. Stan Rose, President of Roche NimbleGen. "The combination of these two Roche technologiesNimbleGen and 454has the potential to transform the market for DNA sequence analysis."


'/>"/>

Contact: Joleen Rau
jrau@nimblegen.com
608-218-7623
Russo Partners, LLC
Source:Eurekalert

Related biology news :

1. Affymetrix Unveils Plans to Double Plant and Animal Genome Microarray Offering
2. Study Demonstrates Gene Expression Microarrays are Comparable and Reproducible
3. Breakthrough Microarray-based Technology for the Study of Cancer
4. Nanogen Issued Patent for Electronic Microarray With Memory
5. An entropy-based gene selection method for cancer classification using microarray data
6. Genrate: a generative model that finds and scores new genes and exons in genomic microarray data
7. Different microarray systems more alike than previously thought
8. Agilent Technologies releases probe sequence, annotation information for all its commercial gene expression microarrays
9. Characterizing Skin Cancer by Microarrays
10. Microarrays as phenotype
11. Agilent Technologies introduces advanced zebrafish, mouse microarrays for stem cell and developmental biology research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... LONDON , April 26, 2016 ... a product subsidiary of Infosys (NYSE: ... to integrate the Onegini mobile security platform with ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration will ... to access and transact across channels. Using this ...
(Date:4/15/2016)... April 15, 2016 Research ... Gait Biometrics Market 2016-2020,"  report to their offering.  ... ) , ,The global gait biometrics market is ... during the period 2016-2020. Gait analysis ... can be used to compute factors that are ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys ... founding CEO, Barrett Bready , M.D., who returned ... of the original technical leadership team, including Chief Technology ... of Product Development, Steve Nurnberg and Vice President of ... to the company. Dr. Bready served as ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... June 27, 2016 , ... Newly ... technologies, services and solutions to the healthcare market. The company's primary focus is ... manufacturing, sales and marketing strategies that are necessary to help companies efficiently bring ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology: